Discloses the use of an alpha5beta1 antagonist antibody and an anti-VEGF antagonist antibody in the manufacture of a medicament for: (A) inhibiting abnormal angiogenesis and/or vascular permeability in a subject suffering from a disease, or (B) treating cancer in a subject, or (C) treating an ocular disease in a subject, or (D) treating an autoimmune disease in a subject, provided the alpha5beta1 antagonist antibody does not comprise: (A) the six hypervariable regions of the antialpha5beta1 antibody produced by the hybridoma deposited as ATCC No. PTA-7420 in the ATCC on March 7, 2006, or (B) the six hypervariable regions of the antialpha5beta1 antibody produced by the hybridoma deposited as ATCC No. PTA-7421 in the ATCC on March 7, 2006. Further discloses related pharmaceutical compositions and kits.
